SEC Form 4
Cadrenal Therapeutics, Inc. (CVKD) insider trading
In the 12 months to Oct 26, 2026, 2 CVKD insiders reported open-market sales of $542.1K across 13 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $542.1K
- 13 filings · 2 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 12 of 13
- $471.8K of $542.1K sold (87%)
Who traded CVKD, and when
- Sale
- Sale, pre-arranged (10b5-1)
CVKD daily close from Oct 27, 2025 to Oct 26, 2026, between $0.87 and $13.67, last $0.91. 13 sale and 0 purchase filings by 2 insiders, marked at their filing dates. Quang X. Pham, CEO and Chairman → Chairman, CEO and Interim CFO → Chairman and CEO: sold $422.5K across 11 filings, first filed Oct 28, 2025, last Jul 1, 2026. Matthew K. Szot, Chief Financial Officer: sold $119.6K across 2 filings, first filed Oct 28, 2025, last Dec 31, 2025.
Largest mark · tap a row for others
Quang X. Pham · Chairman, CEO and Interim CFO
Filing 1 of 2 within a week · $163,646 total
Sale $93,294
22,385 shares at $4.17 avg
Filed Jun 10, 2026 · traded Jun 8
Pre-arranged (10b5-1) · close on filing date $4.14
Quang X. Pham · CEO and Chairman → Chairman, CEO and Interim CFO → Chairman and CEO
CEO and Chairman → Chairman, CEO and Interim CFO → Chairman and CEO
$422.5K soldMatthew K. Szot · Chief Financial Officer
Chief Financial Officer
$119.6K soldOpen-market trades
13 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Quang X. Pham | CEO and Chairman → Chairman, CEO and Interim CFO → Chairman and CEO | $422.5K | — | 11 | 83% of sales | |
| Matthew K. Szot | Chief Financial Officer | $119.6K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Quang X. Pham Chairman and CEO | SalePre-arranged (10b5-1) | 7,400 | $3.03 | $22.4K | 98,589 | |
traded | Quang X. Pham Chairman, CEO and Interim CFO | SalePre-arranged (10b5-1) | 11,156 | $3.04 | $33.9K | 105,989 | |
traded | Quang X. Pham Chairman, CEO and Interim CFO | SalePre-arranged (10b5-1) | 11,444 | $3.48 | $39.8K | 117,145 | |
traded | Quang X. Pham Chairman, CEO and Interim CFO | SalePre-arranged (10b5-1) | 4,126 | $3.18 | $13.1K | 128,589 | |
traded | Quang X. Pham Chairman, CEO and Interim CFO | Sale | 18,124 | $3.88 | $70.4K | 132,715 | |
traded | Quang X. Pham Chairman, CEO and Interim CFO | SalePre-arranged (10b5-1) | 22,385 | $4.17 | $93.3K | 150,839 | |
traded | Quang X. Pham CEO and Chairman | SalePre-arranged (10b5-1) | 8,285 | $4.37 | $36.2K | 173,224 | |
traded | Quang X. Pham CEO and Chairman | SalePre-arranged (10b5-1) | 652 | $4.72 | $3.1K | 181,509 | |
traded | Quang X. Pham CEO and Chairman | SalePre-arranged (10b5-1) | 12,763 | $5.44 | $69.5K | 182,161 | |
traded | Quang X. Pham CEO and Chairman | SalePre-arranged (10b5-1) | 1,165 | $5.69 | $6.6K | 194,924 | |
traded | Matthew K. Szot Chief Financial Officer | SalePre-arranged (10b5-1) | 9,933 | $6.97 | $69.2K | 0 | |
traded | Quang X. Pham CEO and Chairman | SalePre-arranged (10b5-1) | 2,444 | $14.01 | $34.2K | 196,089 | |
traded | Matthew K. Szot Chief Financial Officer | SalePre-arranged (10b5-1) | 3,600 | $13.99 | $50.4K | 9,933 |
GET /stocks/filings/vX/form-4?tickers=CVKD&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"CVKD"
],
"issuer_cik": "0001937993",
"owner_cik": "0001405290",
"accession_number": "0001213900-26-074557",
"form_type": "4",
"filing_date": "2026-07-01",
"period_of_report": "2026-06-29",
"issuer_name": "Cadrenal Therapeutics, Inc.",
"issuer_trading_symbol": "CVKD",
"owner_name": "Pham Quang X",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": true,
"is_other": false,
"officer_title": "Chairman and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-29",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 7400,
"transaction_price_per_share": 3.03,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 98589,
"transaction_value": 22422,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"CVKD"
],
"issuer_cik": "0001937993",
"owner_cik": "0001405290",
"accession_number": "0001213900-26-072789",
"form_type": "4",
"filing_date": "2026-06-26",
"period_of_report": "2026-06-25",
"issuer_name": "Cadrenal Therapeutics, Inc.",
"issuer_trading_symbol": "CVKD",
"owner_name": "Pham Quang X",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": true,
"is_other": false,
"officer_title": "Chairman, CEO and Interim CFO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-06-26",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9029,
"transaction_price_per_share": 3.05,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 105989,
"transaction_value": 27538.449999999997,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Cadrenal Therapeutics, Inc.'s CEO sold stock?
Yes. Quang X. Pham (CEO) sold 99,944 shares ($422.5K) between Oct 2025 and Jul 2026, $352.2K of it under a pre-arranged 10b5-1 plan.
How current is CVKD’s insider data?
These are CVKD Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track CVKD insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for CVKD every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.